Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

166.53USD
21 May 2018
Change (% chg)

$-0.98 (-0.59%)
Prev Close
$167.51
Open
$168.64
Day's High
$168.64
Day's Low
$166.50
Volume
7,076
Avg. Vol
139,858
52-wk High
$168.64
52-wk Low
$128.58

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals Reports Q1 Adjusted Earnings Per Share $2.98
Tuesday, 8 May 2018 

May 8 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $2.98.Q1 GAAP EARNINGS PER SHARE $0.75.Q1 REVENUE $445 MILLION VERSUS I/B/E/S VIEW $434.2 MILLION.Q1 EARNINGS PER SHARE VIEW $2.78 -- THOMSON REUTERS I/B/E/S.UPDATED FINANCIAL GUIDANCE FOR 2018..SEES FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $6.60-$7.70.SEES FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75-$13.25.SEES FULL YEAR 2018 TOTAL NET PRODUCT SALES $1,865 MILLION -$1,910 MILLION.  Full Article

Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea
Friday, 2 Mar 2018 

March 2 (Reuters) - Jazz Pharmaceuticals Plc ::JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NDA FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA.JAZZ PHARMACEUTICALS PLC - SOLRIAMFETOL ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION IS DECEMBER 20, 2018 ​.  Full Article

Jazz Pharmaceuticals Q4 GAAP Earnings Per Share $3.79
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Jazz Pharmaceuticals Plc ::JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2017 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $2.95.Q4 GAAP EARNINGS PER SHARE $3.79.SEES ‍FULL YEAR 2018 REVENUES $1,860 MILLION -$1,930 MILLION ​.SEES ‍FULL YEAR 2018 TOTAL NET PRODUCT SALES $1,845 MILLION -$1,910 MILLION ​.SEES ‍FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $7.15-$8.45​.SEES ‍FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.65-$13.25​.QTRLY ‍TOTAL REVENUES $436.4 MILLION VERSUS $ 396.6 MILLION ​.Q4 EARNINGS PER SHARE VIEW $2.98, REVENUE VIEW $441.3 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $13.07, REVENUE VIEW $1.85 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Jazz Pharmaceuticals Plc ::JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA.JAZZ PHARMACEUTICALS PLC - SUBMISSION OF NDA TO U.S. FDA SEEKING MARKETING APPROVAL FOR SOLRIAMFETOL.  Full Article

Pfenex Earns $18.5 Million In Milestones And Updates Worldwide License And Option Agreement With Jazz Pharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Pfenex Inc ::PFENEX EARNS $18.5 MILLION IN MILESTONES AND UPDATES WORLDWIDE LICENSE AND OPTION AGREEMENT WITH JAZZ PHARMACEUTICALS.PFENEX INC - UNDER AMENDED AGREEMENT, PFENEX WILL BE ELIGIBLE TO RECEIVE AN ADDITIONAL $43.5 MILLION IN AMENDMENT FEE AND DEVELOPMENT MILESTONE PAYMENTS.PFENEX INC - AMENDMENT OF 2016 DEAL THAT GRANTED JAZZ PHARMA RIGHTS TO DEVELOP & COMMERCIALIZE MULTIPLE EARLY STAGE HEMATOLOGY PRODUCT CANDIDATES.  Full Article

Jazz Pharmaceuticals posts Q3 EPS of $1.03
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Jazz Pharmaceuticals Plc :Jazz pharmaceuticals announces third quarter 2017 financial results.Q3 adjusted earnings per share $3.22.Q3 GAAP earnings per share $1.03.Q3 earnings per share view $2.89 -- Thomson Reuters I/B/E/S.Qtrly ‍total revenues $411.9 million versus $374.2 million.Q3 revenue view $420.4 million -- Thomson Reuters I/B/E/S.Sees ‍FY 2017 revenues $1,600 million -$1,650​ million.Sees FY 2017 ‍gaap net income per diluted share $5.30-$6.30​.Sees ‍FY 2017 non-GAAP adjusted net income per diluted share $10.70-$11.20​.FY 2017 earnings per share view $10.89, revenue view $1.64 billion -- Thomson Reuters I/B/E/S.  Full Article

ELSALYS BIOTECH ACQUIRES FROM JAZZ PHARMA WORLDWIDE RIGHTS OF LEUKOTAC
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Elsalys Biotech::ELSALYS BIOTECH ACQUIRES FROM JAZZ PHARMACEUTICALS THE WORLDWIDE RIGHTS OF LEUKOTAC.‍ELSALYS BIOTECH SAYS HAS INITIATED DISCUSSION WITH EUROPEAN HEALTH AUTHORITIES AND WILL ENGAGE IN REGULATORY INTERACTIONS WITH FDA IN 2018​.  Full Article

Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products
Tuesday, 29 Aug 2017 

Aug 29 (Reuters) - Immunogen Inc :Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products.Immunogen will be responsible for development of three ADC programs prior to any potential opt-in by Jazz.Immunogen Inc - as part of agreement, Jazz will pay Immunogen an upfront payment of $75 million.Immunogen Inc - additionally, Jazz will pay Immunogen up to $100 million in development funding over seven years to support three ADC programs.Immunogen - After any opt-in, Jazz would be responsible for any further development as well as for potential regulatory submissions, commercialization.Immunogen - Programs covered under agreement include IMGN779, a CD33-targeted ADC for treatment of acute myeloid leukemia (AML) in Phase 1 testing.Immunogen - Programs under deal also include IMGN632, a CD123-targeted ADC for hematological malignancies seen to enter clinical testing before end of year.  Full Article

Jazz Pharmac announces offering of $500 mln of exchangeable senior notes
Thursday, 17 Aug 2017 

Aug 17 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024.Jazz Pharmaceuticals - to use net proceeds to repay all or substantial portion of $500 million of outstanding borrowings under revolving credit facility.  Full Article

Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Jazz Pharmaceuticals Plc :Jazz Pharmaceuticals announces second quarter 2017 financial results.Q2 adjusted earnings per share $2.56.Q2 GAAP earnings per share $1.72.Q2 earnings per share view $2.75 -- Thomson Reuters I/B/E/S.Jazz Pharmaceuticals Plc says affirming its full year 2017 financial guidance.Qtrly total revenues $394.4 million , up 3 percent.FY2017 earnings per share view $11.02, revenue view $1.66 billion -- Thomson Reuters I/B/E/S.Q2 revenue view $410.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products

* FDA COMMISSIONER SCOTT GOTTLIEB SAYS MAKING PUBLIC LIST OF COS THAT HAVE POTENTIALLY BEEN BLOCKING ACCESS TO THE SAMPLES OF THEIR BRANDED PRODUCTS